Literature DB >> 29572075

Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials.

Joseph M Unger1, Riha Vaidya2, John L Gore3.   

Abstract

Advances in early detection and therapy have increased the number of prostate cancer survivors, leading to a greater emphasis on examining patient-reported outcomes (PROs). PROs augment clinical outcomes, providing a more comprehensive assessment of the patient experience, including symptoms and quality of life, that may impact the overall evaluation of new therapies. The successful incorporation of PROs into clinical trials requires adherence to key design and analysis principles. We present these principles and argue that adherence to these principles is vital to ensure valid interpretation of clinical trial findings, identify meaningful differences among investigational strategies, and better translate clinical trial results to diverse stakeholders.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Patient-reported outcomes; Prostate cancer; Quality of life

Mesh:

Year:  2018        PMID: 29572075      PMCID: PMC6148417          DOI: 10.1016/j.urolonc.2018.02.012

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  40 in total

Review 1.  Response burden and questionnaire length: is shorter better? A review and meta-analysis.

Authors:  Sindre Rolstad; John Adler; Anna Rydén
Journal:  Value Health       Date:  2011-08-02       Impact factor: 5.725

2.  Pattern-mixture models for multivariate incomplete data with covariates.

Authors:  R J Little; Y Wang
Journal:  Biometrics       Date:  1996-03       Impact factor: 2.571

3.  Patient reported outcome measures in practice.

Authors:  Eugene C Nelson; Elena Eftimovska; Cristin Lind; Andreas Hager; John H Wasson; Staffan Lindblad
Journal:  BMJ       Date:  2015-02-10

4.  Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.

Authors:  Donna L Berry; Carol M Moinpour; Caroline S Jiang; Donna Pauler Ankerst; Daniel P Petrylak; Lynne V Vinson; Primo N Lara; Sharon Jones; Mary E Taplin; Patrick A Burch; Maha H A Hussain; E David Crawford
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

5.  Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.

Authors:  Diane Wild; Alyson Grove; Mona Martin; Sonya Eremenco; Sandra McElroy; Aneesa Verjee-Lorenz; Pennifer Erikson
Journal:  Value Health       Date:  2005 Mar-Apr       Impact factor: 5.725

6.  Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form.

Authors:  Ted A Skolarus; Rodney L Dunn; Martin G Sanda; Peter Chang; Thomas K Greenfield; Mark S Litwin; John T Wei
Journal:  Urology       Date:  2015-01       Impact factor: 2.649

7.  Pattern mixture models for longitudinal quality of life studies in advanced stage disease.

Authors:  Donna K Pauler; Sheryl McCoy; Carol Moinpour
Journal:  Stat Med       Date:  2003-03-15       Impact factor: 2.373

8.  How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer.

Authors:  J M Gore; C J Brophy; M A Greenstone
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

9.  Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care.

Authors:  Janet S de Moor; Angela B Mariotto; Carla Parry; Catherine M Alfano; Lynne Padgett; Erin E Kent; Laura Forsythe; Steve Scoppa; Mark Hachey; Julia H Rowland
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-27       Impact factor: 4.254

10.  Long-term functional outcomes after treatment for localized prostate cancer.

Authors:  Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson
Journal:  N Engl J Med       Date:  2013-01-31       Impact factor: 91.245

View more
  3 in total

1.  Measuring pelvic floor disorder symptoms using patient-reported instruments: proceedings of the consensus meeting of the pelvic floor consortium of the American Society of Colon and Rectal Surgeons, the International Continence Society, the American Urogynecologic Society, and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction.

Authors:  L G Bordeianou; J Anger; M Boutros; E Birnbaum; J C Carmichael; K Connell; E J B De; A Mellgren; K Staller; S A Vogler; M M Weinstein; F A Yafi; T Hull
Journal:  Tech Coloproctol       Date:  2019-12-11       Impact factor: 3.781

2.  Assessing quality of life after pulmonary embolism: Comparing results from the PEmb-QoL with semistructured interviews.

Authors:  Jackeline Hernandez-Nino; Mary A Ott; Mary Thomas; Andreia B Alexander; Jeffrey A Kline
Journal:  Res Pract Thromb Haemost       Date:  2022-06-19

3.  Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).

Authors:  Joseph M Unger; Katherine Griffin; Gary W Donaldson; Karen M Baranowski; Margorie J Good; Eunicia Reburiano; Maha Hussain; Paul J Monk; Peter J Van Veldhuizen; Michael A Carducci; Celestia S Higano; Primo N Lara; Catherine M Tangen; David I Quinn; James L Wade; Nicholas J Vogelzang; Ian M Thompson; Carol M Moinpour
Journal:  J Patient Rep Outcomes       Date:  2018-06-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.